Skip to main content

Table 1 Response assessment during the remission induction therapy

From: Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient

Days after the start of administration -1 14 28 42 56
Nuclear cell count (× 104/μL) 6.0 7.0 10.0 12.0 4.0
Blast+Promyelocyte (%) 5.8 17.8 0.8 1.2 0.6
Myeloid (%) 51.2 32.6 29.4 21.6 34.2
Erythroid (%) 22.6 28.8 55.0 70.0 33.2
Others (%) 20.4 20.8 14.8 7.2 32.0
PML-RARα FISH (%) 5.0 83.0 33.0 9.0 0.0
CD11b (%) 5.0 27.0 43.2 59.3 ND
CD15 (%) 8.6 23.2 38.5 47.2 ND
CD117 (%) 94.5 30.4 41.3 23.9 ND
CD34 (%) 38.0 14.4 26.2 15.8 ND
  1. BM aspirations were collected before the treatment start (day -1), and 14, 28, 42, and 56 days after the start of administration. Response assessment was evaluated by BM aspirate examination, FISH analysis and the expression levels of cell surface markers. ND: no data.